DataVXAdvanced MaterialsPaper
journal article·2023-09Open access

Induction of Tumor Ferroptosis‐Dependent Immunity via an Injectable Attractive Pickering Emulsion Gel

Xiaomeng Dai, Jia Zhang, Xuanwen Bao, Yixuan Guo, Yuzhi Jin, Chenjing Yang, Hangyu Zhang, Lulu Liu, Yang Gao, Chanqi Ye, Wei Wu, Chuan Liu, Chun‐Xia Zhao, Jianpeng Sheng, En Ren, Hongjun Li, Weijia Fang, Baiheng Wu, Jian Ruan, Zhen Gu, Dong Chen, Peng Zhao

Advanced Materials· Volume 35· Issue 35
Publisher pageOpen full text
Source abstract

Abstract

Abstract The combination of ferroptosis inducers and immune checkpoint blockade can enhance antitumor effects. However, the efficacy in tumors with low immunogenicity requires further investigation. In this work, a water‐in‐oil Pickering emulsion gel is developed to deliver (1S, 3R)‐RSL‐3 (RSL‐3), a ferroptosis inducer dissolved in iodized oil, and programmed death‐1 (PD‐1) antibody, the most commonly used immune checkpoint inhibitor dissolved in water, with optimal characteristics (RSL‐3 + PD‐1@gel). Tumor lipase degrades the continuous oil phase, which results in the slow release of RSL‐3 and PD‐1 antibody and a notable antitumor effect against low‐immunogenic hepatocellular carcinoma and pancreatic cancer. Intriguingly, the RSL‐3 + PD‐1@gel induces ferroptosis of tumor cells, resulting in antitumor immune response via accumulation of helper T lymphocyte cells and cytotoxic T cells. Additionally, the single‐cell sequence profiling analysis during tumor treatment reveals the induction of ferroptosis in tumor cells together with strong antitumor immune response in ascites.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Ferroptosis and cancer prognosis · Immune cells in cancer · Cancer Immunotherapy and Biomarkers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Medical Oncology The First Affiliated Hospital School of Medicine Zhejiang University #79 Qingchun Road Hangzhou Zhejiang Province 310003 P. R. China

College of Energy Engineering and State Key Laboratory of Clean Energy Utilization Zhejiang University Hangzhou 310027 China

Australian Institute for Bioengineering and Nanotechnology The University of Queensland St Lucia QLD 4072 Australia

The First Affiliated Hospital of Zhejiang University School of Medicine Zhejiang Provincial Key Laboratory of Pancreatic Disease Hangzhou 310027 China

Zhejiang Provincial Key Laboratory for Advanced Drug Delivery Systems College of Pharmaceutical Sciences Zhejiang University Hangzhou 310058 China

Liangzhu Laboratory Zhejiang University Medical Center Hangzhou 311121 China

MOE Key Laboratory of Macromolecular Synthesis and Functionalization Department of Polymer Science and Engineering Zhejiang University Hangzhou 310027 China

Department of Hepatobiliary and Pancreatic Surgery the Second Affiliated Hospital School of Medicine Zhejiang University Hangzhou Zhejiang 310009 China

College of Material Chemistry and Chemical Engineering Hangzhou Normal University Hangzhou 311121 China

Metabolic Hepatobiliary and Pancreatic Diseases Key Laboratory of Luzhou City The Affiliated Hospital of Southwest Medical University Luzhou Sichuan China

Jinhua Institute of Zhejiang University Jinhua 321299 China

Department of General Surgery Sir Run Run Hospital School of Medicine Zhejiang University Hangzhou 310016 China

Funding

National Natural Science Foundation of China

References (45)

Show source-provided references
1. 10.1016/j.immuni.2019.12.01110.1016/j.immuni.2019.12.011 ↗
2. 10.1038/s41422-020-0343-410.1038/s41422-020-0343-4 ↗
3. 10.1200/JCO.2014.59.435810.1200/JCO.2014.59.4358 ↗
4. 10.1016/j.ccell.2015.03.00110.1016/j.ccell.2015.03.001 ↗
5. 10.1038/s41571-021-00552-710.1038/s41571-021-00552-7 ↗
6. 10.1200/JCO.21.0149710.1200/JCO.21.01497 ↗
7. 10.1016/j.ccell.2020.08.00410.1016/j.ccell.2020.08.004 ↗
8. 10.7150/thno.5464810.7150/thno.54648 ↗
9. 10.1136/jitc-2020-00143710.1136/jitc-2020-001437 ↗
10. 10.1016/j.jhep.2019.09.02510.1016/j.jhep.2019.09.025 ↗
11. 10.1038/s41571-021-00573-210.1038/s41571-021-00573-2 ↗
12. 10.1158/2159-8290.CD-20-168010.1158/2159-8290.CD-20-1680 ↗
13. 10.1016/j.cej.2021.13010910.1016/j.cej.2021.130109 ↗
14. 10.1038/s41571-020-00462-010.1038/s41571-020-00462-0 ↗
15. 10.1126/sciadv.aay978910.1126/sciadv.aay9789 ↗
16. 10.1038/s41568-022-00459-010.1038/s41568-022-00459-0 ↗
17. 10.1016/j.cell.2022.06.00310.1016/j.cell.2022.06.003 ↗
18. 10.1016/j.ccell.2019.04.00210.1016/j.ccell.2019.04.002 ↗
19. 10.1002/adma.20210115510.1002/adma.202101155 ↗
20. 10.1016/j.cell.2013.12.01010.1016/j.cell.2013.12.010 ↗
21. 10.1126/scitranslmed.aat797310.1126/scitranslmed.aat7973 ↗
22. 10.7150/thno.4238510.7150/thno.42385 ↗
23. 10.1126/scitranslmed.aan368210.1126/scitranslmed.aan3682 ↗
24. 10.1016/j.tifs.2019.02.04310.1016/j.tifs.2019.02.043 ↗
25. 10.1038/s41578-019-0161-910.1038/s41578-019-0161-9 ↗
26. 10.1038/nnano.2017.18210.1038/nnano.2017.182 ↗
27. 10.1016/j.cell.2017.09.02110.1016/j.cell.2017.09.021 ↗
28. 10.1126/scitranslmed.abc892210.1126/scitranslmed.abc8922 ↗
29. 10.1186/s40425-019-0650-910.1186/s40425-019-0650-9 ↗
30. 10.1038/s41577-019-0127-610.1038/s41577-019-0127-6 ↗
31. 10.1016/j.cellimm.2018.01.00310.1016/j.cellimm.2018.01.003 ↗
32. 10.1016/j.ccell.2021.05.00610.1016/j.ccell.2021.05.006 ↗
33. 10.1002/hep.2845310.1002/hep.28453 ↗
34. 10.1016/j.jhep.2011.10.02110.1016/j.jhep.2011.10.021 ↗
35. 10.1002/adma.20180695710.1002/adma.201806957 ↗
36. 10.1002/adma.20180152710.1002/adma.201801527 ↗
37. 10.1021/acsnano.7b0814810.1021/acsnano.7b08148 ↗
38. 10.1016/j.ccell.2022.02.00310.1016/j.ccell.2022.02.003 ↗
39. Jiang Z. · J. Clin. Invest. · 2021 · 15 · 131
40. 10.1158/2159-8290.CD-19-033810.1158/2159-8290.CD-19-0338 ↗
41. 10.1001/jamaoncol.2019.540910.1001/jamaoncol.2019.5409 ↗
42. 10.1016/j.jhep.2015.10.02910.1016/j.jhep.2015.10.029 ↗
43. 10.1016/j.cell.2019.10.00310.1016/j.cell.2019.10.003 ↗
44. 10.1002/adma.20210236210.1002/adma.202102362 ↗
45. 10.1021/acs.chemrev.0c0117710.1021/acs.chemrev.0c01177 ↗